National Research (NRC) Competitors

Astrana Health (NASDAQ:ASTH) and National Research (NASDAQ:NRC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Does the MarketBeat Community prefer ASTH or NRC?

National Research received 95 more outperform votes than Astrana Health when rated by MarketBeat users. However, 80.00% of users gave Astrana Health an outperform vote while only 61.67% of users gave National Research an outperform vote.

Company	Underperform	Outperform
Astrana Health	Outperform Votes 16 80.00%	Underperform Votes 4 20.00%
National Research	Outperform Votes 111 61.67%	Underperform Votes 69 38.33%

Do institutionals and insiders believe in ASTH or NRC?

52.8% of Astrana Health shares are held by institutional investors. Comparatively, 47.3% of National Research shares are held by institutional investors. 20.0% of Astrana Health shares are held by company insiders. Comparatively, 8.1% of National Research shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is ASTH or NRC more profitable?

National Research has a net margin of 17.32% compared to Astrana Health's net margin of 3.63%. National Research's return on equity of 66.52% beat Astrana Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	3.63%	9.37%	5.32%
National Research	17.32%	66.52%	20.00%

Do analysts recommend ASTH or NRC?

Astrana Health presently has a consensus price target of $53.29, suggesting a potential upside of 101.00%. Given Astrana Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Astrana Health is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
National Research	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has higher earnings and valuation, ASTH or NRC?

Astrana Health has higher revenue and earnings than National Research. National Research is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$2.25B	0.66	$60.72M	$0.72	36.82
National Research	$141.30M	2.64	$24.78M	$1.03	15.87

Which has more risk & volatility, ASTH or NRC?

Astrana Health has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, National Research has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Does the media refer more to ASTH or NRC?

In the previous week, Astrana Health had 3 more articles in the media than National Research. MarketBeat recorded 8 mentions for Astrana Health and 5 mentions for National Research. Astrana Health's average media sentiment score of 1.40 beat National Research's score of 0.56 indicating that Astrana Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrana Health	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Research	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Astrana Health beats National Research on 12 of the 18 factors compared between the two stocks.